Advertisement

Editorial: bio-markers as tools for discovery of new psoriasis therapies.

16:57 EDT 20th May 2013 | BioPortfolio

Summary of "Editorial: bio-markers as tools for discovery of new psoriasis therapies."

No Summary Available

Affiliation

Drug Development, AstraZeneca R & D, Alderley Park, Macclesfield Cheshire, SK10 4TH, United Kingdom.

Journal Details

This article was published in the following journal.

Name: Current drug discovery technologies
ISSN: 1875-6220
Pages: 1

Links

Medical and Biotech [MESH] Definitions

Editorial Policies

The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.

Sensory Art Therapies

Therapies using arts or directed at the senses.

Comment

Work consisting of a critical or explanatory note written to discuss, support, or dispute an article or other presentation previously published. It may take the form of an article, letter, editorial, etc. It appears in publications under a variety of names: comment, commentary, editorial comment, viewpoint, etc.

Fetal Therapies

Prenatal interventions to correct fetal anomalies or treat FETAL DISEASES in utero. Fetal therapies include several major areas, such as open surgery; FETOSCOPY; pharmacological therapy; INTRAUTERINE TRANSFUSION; STEM CELL TRANSPLANTATION; and GENE THERAPY.

Psoriasis

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

PubMed Articles [ 11744 Associated PubMed Articles listed on BioPortfolio]

Pustulosis palmoplantaris is a disease distinct from psoriasis.

Abstract Pustulosis palmoplantaris (PPP) is a chronic inflammatory skin disease with a considerable impairment of quality of life and is characterized by sterile pustules and red, scaly skin on the pa...

Scalp psoriasis: an overview of the disease and available therapies.

The scalp is one of the regions of the body most commonly affected by psoriatic lesions. While the head represents only 10 percent of the body's surface area, the consequences of scalp psoriasis are d...

Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation.

An association between obesity and psoriasis has been reported. For a variety of reasons, obese persons with psoriasis are often more difficult to treat. We sought to review the literature on obesity...

Current therapeutic approaches of psoriasis are affected by age at disease onset.

Abstract Psoriasis in patients with early onset follows an irregular course with tendency to become severe and extensive. The aim of this study was to look for an association between age at onset of p...

Diagnosis and Treatment of Pediatric Psoriasis: Current and Future.

Psoriasis is a common yet complex inflammatory dermatosis that may be seen in infants, children, and adolescents. The clinical presentation and course may be quite variable, and while patients with mi...

Clinical Trials [ 2061 Associated Clinical Trials listed on BioPortfolio]

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in patients with plaque psoriasis, and other overlapping forms of psoriasis (such as plaque psoria...

A Study of Efalizumab in Patients With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

Phase IIIb , open-label, multi-centre study in patients receiving efalizumab 1mg/kg/week for 12 weeks. At anytime during the first 12 weeks, non-responding or worsening patients will dis...

A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies

This is a Phase IIIb, open label, uncontrolled, multicenter study designed to evaluate the safety and tolerability of 12 weeks of subcutaneously administered efalizumab in subjects with mo...

A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis

In recent years, biologics have changed the treatment of psoriasis, giving us additional therapeutic options that are potentially less toxic to the liver, kidneys, and bone marrow and are...

Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis

Psoriasis is a chronic, often severe, autoimmune condition that affects approximately 2% of the world's population. The epidemiology of pediatric psoriasis has not been well documented and...

Search BioPortfolio: